182 related articles for article (PubMed ID: 33863896)
61. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
Quek RGW; Mardekian J
Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
[TBL] [Abstract][Full Text] [Related]
62. The prognosis and risk factors for capecitabine maintenance treatment in metastatic breast cancer: a retrospective comparative cohort study.
Tian C; Yang J; Xie N; Tang Y; Zhou H; Hu ZY; Ouyang Q
Ann Transl Med; 2022 Sep; 10(17):924. PubMed ID: 36172110
[TBL] [Abstract][Full Text] [Related]
63. Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer.
Corbaux P; Lardy-Cleaud A; Alexandre M; Fontanilles M; Lévy C; Viansone AA; Mailliez A; Debled M; Goncalves A; Le Du F; Lerebours F; Ferrero JM; Eymard JC; Mouret-Reynier MA; Petit T; Frenel JS; Dalenc F; Courtinard C; Chaix M; Bachelot T
Breast Cancer Res Treat; 2022 Jan; 191(1):191-207. PubMed ID: 34687411
[TBL] [Abstract][Full Text] [Related]
64. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
65. Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
Thangarajah F; Vogel C; Pahmeyer C; Eichler C; Holtschmidt J; Ratiu D; Mallmann P; Malter W
Anticancer Res; 2018 Oct; 38(10):6023-6026. PubMed ID: 30275235
[TBL] [Abstract][Full Text] [Related]
66. Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis.
Brufsky A; Liu X; Li B; McRoy L; Layman RM
Front Oncol; 2022; 12():865292. PubMed ID: 35860587
[TBL] [Abstract][Full Text] [Related]
67. Impact of metastatic estrogen receptor and progesterone receptor status on survival.
Lower EE; Glass EL; Bradley DA; Blau R; Heffelfinger S
Breast Cancer Res Treat; 2005 Mar; 90(1):65-70. PubMed ID: 15770528
[TBL] [Abstract][Full Text] [Related]
68. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
Zhu YY; Si W; Ji TF; Guo XQ; Hu Y; Yang JL
Tumour Biol; 2016 Jun; 37(6):7675-84. PubMed ID: 26687919
[TBL] [Abstract][Full Text] [Related]
69. Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer.
DeMichele A; Robert N; Chen C; Kim S; Zhang Z; Lu DR; Aguilar KM; Wang Y; Li B; Schneeweiss S; Rassen JA; Gaffney M; McRoy L
Target Oncol; 2023 Jul; 18(4):543-558. PubMed ID: 37428347
[TBL] [Abstract][Full Text] [Related]
70. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
71. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status.
Park YH; Lee S; Cho EY; Choi YL; Lee JE; Nam SJ; Yang JH; Ahn JS; Im YH
Cancer Chemother Pharmacol; 2010 Aug; 66(3):507-16. PubMed ID: 19956951
[TBL] [Abstract][Full Text] [Related]
72. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.
Tripathy D; Kaufman PA; Brufsky AM; Mayer M; Yood MU; Yoo B; Quah C; Yardley D; Rugo HS
Oncologist; 2013; 18(5):501-10. PubMed ID: 23652380
[TBL] [Abstract][Full Text] [Related]
73. Surgery of primary tumour has survival benefit in metastatic breast cancer with single-organ metastasis, especially bone.
Rhu J; Lee SK; Kil WH; Lee JE; Nam SJ
ANZ J Surg; 2015 Apr; 85(4):240-4. PubMed ID: 25996008
[TBL] [Abstract][Full Text] [Related]
74. Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study.
Miller RS; Mokiou S; Taylor A; Sun P; Baria K
Breast Cancer Res Treat; 2022 May; 193(1):83-94. PubMed ID: 35194731
[TBL] [Abstract][Full Text] [Related]
75. Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution.
Chen R; Qarmali M; Siegal GP; Wei S
Mod Pathol; 2020 Dec; 33(12):2499-2506. PubMed ID: 32620918
[TBL] [Abstract][Full Text] [Related]
76. Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival.
Fan Y; Wang Y; He L; Imani S; Wen Q
ESMO Open; 2021 Aug; 6(4):100232. PubMed ID: 34392135
[TBL] [Abstract][Full Text] [Related]
77. Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases.
Trillo P; Sandoval J; Trapani D; Nicolò E; Zagami P; Giugliano F; Tarantino P; Vivanet G; Ascione L; Friedlaender A; Esposito A; Criscitiello C; Curigliano G
Eur J Cancer; 2023 May; 185():119-130. PubMed ID: 36989828
[TBL] [Abstract][Full Text] [Related]
78. Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort.
Frank S; Carton M; Dubot C; Campone M; Pistilli B; Dalenc F; Mailliez A; Levy C; D'Hondt V; Debled M; Vermeulin T; Coudert B; Perrin C; Gonçalves A; Uwer L; Ferrero JM; Eymard JC; Petit T; Mouret-Reynier MA; Patsouris A; Guesmia T; Bachelot T; Robain M; Cottu P
Breast; 2020 Aug; 52():50-57. PubMed ID: 32380440
[TBL] [Abstract][Full Text] [Related]
79. Elucidating Determinants of Survival Disparities Among a Real-world Cohort of Metastatic Breast Cancer Patients: A National Cancer Database Analysis.
Statler AB; Wei W; Gupta A; Blake CN; Hobbs BP; Nahleh ZA
Clin Breast Cancer; 2020 Oct; 20(5):e625-e650. PubMed ID: 32434711
[TBL] [Abstract][Full Text] [Related]
80. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer.
Finn RS; Press MF; Dering J; Arbushites M; Koehler M; Oliva C; Williams LS; Di Leo A
J Clin Oncol; 2009 Aug; 27(24):3908-15. PubMed ID: 19620495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]